Z Gastroenterol 2025; 63(08): e507
DOI: 10.1055/s-0045-1810882
Abstracts | DGVS/DGAV
Kurzvorträge
AEG & Magenkarzinom Donnerstag, 18. September 2025, 17:05 – 18:33, Vortragsraum 11

Collagen turnover biomarkers to predict outcome of patients with gastric cancer

L Kaps
1   Saarland University Medical Center, Department of Medicine II, Homburg, Deutschland
,
M A Genc
2   University Medical Center of the Johannes Gutenberg-University, First Department of Medicine, Mainz, Deutschland
,
M Moehler
2   University Medical Center of the Johannes Gutenberg-University, First Department of Medicine, Mainz, Deutschland
,
S Grabbe
3   University Medical Center of the Johannes Gutenberg-University, Department of Dermatology, Mainz, Deutschland
,
S C Sadiq
1   Saarland University Medical Center, Department of Medicine II, Homburg, Deutschland
,
P Schneider
3   University Medical Center of the Johannes Gutenberg-University, Department of Dermatology, Mainz, Deutschland
,
J M Schattenberg
1   Saarland University Medical Center, Department of Medicine II, Homburg, Deutschland
,
D Schuppan
1   Saarland University Medical Center, Department of Medicine II, Homburg, Deutschland
,
R S Pedersen
4   Nordic Bioscience A/S, Herlev, Dänemark
,
M A Karsdal
4   Nordic Bioscience A/S, Herlev, Dänemark
,
A Maderer
2   University Medical Center of the Johannes Gutenberg-University, First Department of Medicine, Mainz, Deutschland
,
N Willumsen
4   Nordic Bioscience A/S, Herlev, Dänemark
› Author Affiliations
› Further Information
Also available ateRef
 

Background: The tumor stroma plays a pivotal role in gastric cancers (GC). Circulating collagen turnover markers of type I collagen (reC1M), type III collagen (PRO-C3 and C3M), type IV collagen (C4G), type VIII collagen (PRO-C8 and TUM), type XI collagen (PRO-C11) and type XVII collagen (PRO-C17) may be used as potential non-invasive biomarkers.

Methods: Eight biomarkers of collagen turnover were assessed in 74 patients with GC and compared to 50 healthy volunteers. The diagnostic and prognostic value of the markers was evaluated for overall survival (OS) and progression-free survival (PFS).

Results: With the exception of C4G, all collagen turnover markers were significantly elevated (p<0.001) in the serum of patients with gastric cancer (GC) compared to healthy controls at baseline. C3M demonstrated the strongest discriminatory power, achieving an AUROC of 0.88 (95% CI 0.81; 0.95) with a balanced sensitivity (78%) and specificity (77%). Patients with high levels of reC1M (HR 2.69, 95% CI 1.18; 6.15), followed by C3M (HR 2.12, 95% CI 1.17; 4.17), PRO-C11 (HR 2.04, 95% CI 1.05; 3.98) and TUM (HR 1.91, 95% CI 0.98; 3.74) had a significantly shorter OS after adjusting for relevant risk factors, including CA 19-9 and CEA at baseline, age, presence of metastases, BMI, and sex. In contrast, none of the established tumor markers, CA 19-9, CEA, or CA 72.4 remained prognostic of OS. In a longitudinal analysis, patients who exhibited a reduction of greater than 20% in PRO-C3 and PRO-C11 biomarker levels from baseline to post-first CTX had a longer overall survival (OS) compared to non-responders.

Conclusion: The collagen turnover markers reC1M, C3M, TUM and PRO-11 were prognostic for OS in patients with GC, while the established tumor markers 19-9, CEA, or CA 72.4 had no prognostic value. C3M showed the best diagnostic performance to discriminate between patients with GC and controls.



Publication History

Article published online:
04 September 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany